Form 4: Oruka Therapeutics Director Carl Dambkowski Granted 17,500 Stock Options

Oruka Therapeutics, Inc. Director Carl Dambkowski was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Summary

• Carl Dambkowski, a Director of Oruka Therapeutics, Inc. (ORKA), acquired 17,500 stock options.
• The transaction date for the option grant was June 2, 2025.
• The exercise price for these stock options is $11.77 per share.
• The options will vest as to 1/12 of the underlying shares monthly, commencing from June 2, 2025.
• The expiration date for these stock options is June 1, 2035.
• Following this transaction, Carl Dambkowski beneficially owns 17,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects standard compensation practices that align director interests with shareholders, indicating stability in governance and incentive structures. It is not highly impactful on its own but contributes to overall positive corporate governance.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The vesting schedule indicates that the director's beneficial ownership of the underlying common stock will increase gradually over the next 12 months, subject to continued service.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and board compensation packages across various industries, including biotechnology.
• The vesting schedule of 1/12 monthly over a year is a common approach to ensure continued commitment and retention.

Related Party Transactions

• Grant of 17,500 stock options to Carl Dambkowski, a Director of Oruka Therapeutics, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for equity participation within the company.

Next Steps

• The stock options will vest monthly over the next year, starting June 2, 2025, allowing Carl Dambkowski to exercise them as they vest.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Carl Dambkowski, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule